214 related articles for article (PubMed ID: 31575545)
1. Heterogeneous beta-catenin activation is sufficient to cause hepatocellular carcinoma in zebrafish.
Kalasekar SM; Kotiyal S; Conley C; Phan C; Young A; Evason KJ
Biol Open; 2019 Oct; 8(10):. PubMed ID: 31575545
[TBL] [Abstract][Full Text] [Related]
2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
3. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
4. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
6. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
[TBL] [Abstract][Full Text] [Related]
7. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Loesch R; Caruso S; Paradis V; Godard C; Gougelet A; Renault G; Picard S; Tanaka I; Renoux-Martin Y; Perret C; Taketo MM; Zucman-Rossi J; Colnot S
J Hepatol; 2022 Aug; 77(2):424-435. PubMed ID: 35257829
[TBL] [Abstract][Full Text] [Related]
8. WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities.
Gajos-Michniewicz A; Czyz M
Genes Dis; 2024 Mar; 11(2):727-746. PubMed ID: 37692481
[TBL] [Abstract][Full Text] [Related]
9. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
10. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
11. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
[TBL] [Abstract][Full Text] [Related]
12. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
[TBL] [Abstract][Full Text] [Related]
13. High Frequency of β-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist.
Mattu S; Saliba C; Sulas P; Zavattari P; Perra A; Kowalik MA; Monga SP; Columbano A
Am J Pathol; 2018 Nov; 188(11):2497-2507. PubMed ID: 30201494
[TBL] [Abstract][Full Text] [Related]
14. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1.
Devereux TR; Stern MC; Flake GP; Yu MC; Zhang ZQ; London SJ; Taylor JA
Mol Carcinog; 2001 Jun; 31(2):68-73. PubMed ID: 11429783
[TBL] [Abstract][Full Text] [Related]
15. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
[TBL] [Abstract][Full Text] [Related]
17. N
Wei H; Huang L; Lu Q; Huang Z; Huang Y; Xu Z; Li W; Pu J
J Hepatocell Carcinoma; 2023; 10():1991-2007. PubMed ID: 37954496
[TBL] [Abstract][Full Text] [Related]
18. β-Catenin signaling in hepatocellular carcinoma.
Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
[TBL] [Abstract][Full Text] [Related]
19. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.
Aoki T; Nishida N; Kurebayashi Y; Sakai K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Ueshima K; Minami Y; Tsurusaki M; Nakai T; Sakamoto M; Nishio K; Kudo M
Liver Cancer; 2024 Jun; 13(3):285-305. PubMed ID: 38894812
[TBL] [Abstract][Full Text] [Related]
20. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
